The Efficacy and Safety of Azelaic Acid 15% Foam in the Treatment of Facial Acne Vulgaris

June 2018 | Volume 17 | Issue 6 | Original Article | 641 | Copyright © June 2018

Peter W. Hashim MD MHS,a Tinley Chen BA,a Julie C. Harper MD,b and Leon H. Kircik MDa,c,d

aThe Icahn School of Medicine at Mount Sinai, Department of Dermatology, New York, NY bThe Dermatology and Skin Care Center of Birmingham, Birmingham, AL cIndiana University School of Medicine, Indianapolis, IN dPhysicians Skin Care PLLC, Louisville, KY

Table 2severity, seriousness, causal relationship to the study medication, and the course of action taken.

Statistical Analyses

Analyses of efficacy endpoints were based on data from subjects who completed the study. All statistical tests were two-sided and interpreted at a 5% significance level. Changes in FIGA as well as total, inflammatory, and non-inflammatory lesion count were evaluated using the Wilcoxon signed-rank test. The incidence and severity of all adverse and/or unexpected events was tabulated and classified by intensity and relationship to the study medication. 



Twenty subjects with moderate-to-severe facial acne vulgaris were enrolled (Table 4). The average age was 26 years, with ages ranging from 18 to 39 years. All subjects were female, ofTable 3which 75% were white, 20% were black, and 5% were of mixed race. All study subjects were treated with azelaic acid 15% foam for 16 weeks. All subjects completed the 16-week study period, with the exception of 1 subject who was lost to follow-up (moved away) after week 8.


Facial Investigator Global Assessment (FIGA)There was a significant reduction in FIGA scores from baseline to week 16 (p = 0.0004). At baseline, 18 subjects had a FIGA score of 3 (moderate), and 1 subject had a FIGA score of 4 (severe). 12 subjects (63%) were Clear or Almost Clear by week 16. 16 subjects (84%) experienced at least a 1-grade improvement, and 12 subjects (63%) experienced at least a 2-grade improvement by week 16.Table 4